resistant depression

(Part two of a four-part series) See previous story in this series: Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS’ Latest Trial Outcomes COMPASS (NASDAQ: CMPS)’ Phase 2 trial published results elicited several comments from experts in the field as well as...